Amgen's Nplate prompts NICE turnaround on GSK's Revolade
This article was originally published in Scrip
Two years after it initially said no, NICE, the health technology appraisal institute for England and Wales, looks set to recommend GlaxoSmithKline's thrombopoietin receptor agonist Revolade (eltrombopag) for chronic immune (idiopathic) thrombocytopenic purpura (ITP). The institute decided to review the guidance after GSK offered a discount on the drug and after the institute recommended a key comparator, Amgen's Nplate, explained GSK.
You may also be interested in...
Financial ties between companies and healthcare bodies distort the production and use of evidence, claims a paper co-authored by researchers, clinicians and decision makers, including a representative of Germany’s HTA body, IQWiG.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
Softening provisions to make EU-wide joint clinical assessments voluntary would make proposed legislation on HTA cooperation redundant, says Eurordis.